In one paragraphArticle in American journal of physiology. Renal physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Yujiro MaeokaDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University, Portland, Oregon, United States.ORCID 0000-0003-1808-2772 Tanner BradfordDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University, Portland, Oregon, United States.
Xiao-Tong SuDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University, Portland, Oregon, United States.ORCID 0000-0001-8121-8105 Avika SharmaDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University, Portland, Oregon, United States.ORCID 0000-0002-7979-0820 Chao-Ling YangDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University, Portland, Oregon, United States.
David H EllisonDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University, Portland, Oregon, United States.ORCID 0000-0003-2915-265X James A McCormickDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University, Portland, Oregon, United States.ORCID 0000-0003-4000-6653 Ryan J CorneliusDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University, Portland, Oregon, United States.ORCID 0000-0002-1389-1493 Funding
WNK Kinase Regulation of Thiazide-sensitive NaCl TransportR01DK051496 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI David Hoadley Ellison, CHAO-LING YANG · 1998 to 2026
$8.4MRegulation of sodium transport and blood pressure by SPAK/OSR1 kinasesR01DK098141 · NIDDK · OREGON HEALTH & SCIENCE UNIVERSITY · PI JAMES A MCCORMICK, Ujwal Shinde · 2014 to 2026
$4.2MRole of the COP9 Signalosome (CSN) in kidney disease and hypertensionK01DK120790 · NIDDK · OREGON HEALTH & SCIENCE UNIVERSITY · PI CORNELIUS, RYAN J · 2020 to 2024
$650kThe role of the COP9 signalosome in distal nephron remodelingR03DK137034 · NIDDK · OREGON HEALTH & SCIENCE UNIVERSITY · PI CORNELIUS, RYAN J · 2023 to 2023
$231kPROP-1 AND PITUITARY DEVELOPMENTF32DK009814 · NIDDK · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI LI, XUE SEAN · 1998 to 2001
$80kFondation Leducq (Leducq Foundation) 17CVD05HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK09814HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK120790HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK137034HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK51496NIDDK NIH HHS K01 DK120790NIDDK NIH HHS R01 DK051496NIDDK NIH HHS R01 DK098141NIDDK NIH HHS R03 DK137034Uehara Memorial Foundation (UMF)
6 · The paper itselfAbstract
The disease familial hyperkalemic hypertension (FHHt; also known as Gordon syndrome) is caused by aberrant accumulation of with-no-lysine kinase (WNK4) activating the NaCl cotransporter (NCC) in the distal convoluted tubule (DCT) of the kidney. Mutations in cullin 3 (CUL3) cause FHHt by disrupting interaction with the deneddylase COP9 signalosome (CSN). Deletion of
Indexed as
COP9 Signalosome ComplexCullin ProteinsKidney Tubules, DistalMice, KnockoutAnimalsDisease Models, AnimalMicePeptide HydrolasesPhenotypeProtein Serine-Threonine KinasesPseudohypoaldosteronismSignal TransductionSolute Carrier Family 12, Member 3COP9 Signalosome ComplexCul3 protein, mouseCullin ProteinsPeptide HydrolasesProtein Serine-Threonine KinasesSlc12a3 protein, mouseSolute Carrier Family 12, Member 3COP9 signalosomecullin 3distal convoluted tubuleWNK
Identifiers
PMID39205661
PMCPMC11483082
What OpenQuestion holds
Textmetadata
Read underepoch 390